Filter by cancer type, molecular target, phase, and recruitment status.
Loading filters…
Melanoma · Pancreas · Multiple / solid tumors
Research area: personalized mRNA vaccines. KEYNOTE-942, V940 phase III, and pancreas vaccine cards are listed separately underneath.
Evidence level: Randomized phase IIb results in melanoma plus phase III confirmation trials; early clinical in pancreas.
Not a single trial · 3 linked records
Pancreas · Multiple / solid tumors
Research area: protein degradation. Setidegrasib (KRAS G12D) clinical card underneath; separate from classic inhibitor cards.
Evidence level: 2026 phase I clinical activity signal for KRAS G12D degrader setidegrasib (ASP3082) in NEJM; not standard care.
Not a single trial · 1 linked records
Gastric / esophageal · Biliary tract · Multiple / solid tumors
Research area: BsADCs. BL-B01D1 esophagus/biliary phase III cards underneath; zanidatamab is not an ADC.
Evidence level: Some molecules in phase III / regional programs; izalontamab brengitecan (BL-B01D1) as an example. Not all BsADCs are equivalent.
Not a single trial · 2 linked records
Multiple / solid tumors
Research area: armored CAR-T. Early-phase ARMADA example underneath; do not conflate with hematologic CAR-T.
Evidence level: Mostly early clinical (phase I) in solid tumors. Hematologic CAR-T success does not automatically transfer.
Not a single trial · 1 linked records
4 / 51 studies · “Emerging treatment technologies” only
Melanoma · Pancreas · Multiple / solid tumors
Research area: personalized mRNA vaccines. KEYNOTE-942, V940 phase III, and pancreas vaccine cards are listed separately underneath.
Evidence level: Randomized phase IIb results in melanoma plus phase III confirmation trials; early clinical in pancreas.
Not a single trial · 3 linked records
Pancreas · Multiple / solid tumors
Research area: protein degradation. Setidegrasib (KRAS G12D) clinical card underneath; separate from classic inhibitor cards.
Evidence level: 2026 phase I clinical activity signal for KRAS G12D degrader setidegrasib (ASP3082) in NEJM; not standard care.
Not a single trial · 1 linked records
Gastric / esophageal · Biliary tract · Multiple / solid tumors
Research area: BsADCs. BL-B01D1 esophagus/biliary phase III cards underneath; zanidatamab is not an ADC.
Evidence level: Some molecules in phase III / regional programs; izalontamab brengitecan (BL-B01D1) as an example. Not all BsADCs are equivalent.
Not a single trial · 2 linked records
Multiple / solid tumors
Research area: armored CAR-T. Early-phase ARMADA example underneath; do not conflate with hematologic CAR-T.
Evidence level: Mostly early clinical (phase I) in solid tumors. Hematologic CAR-T success does not automatically transfer.
Not a single trial · 1 linked records